SLRX Salarius: Bozor kapitallashuvining balans qiymatiga nisbati

Salarius (SLRX) - korporativ logo

Salarius Pharmaceuticals patentlangan ferment inhibitorlari orqali noyob aniqlikdagi onkologik terapiya tarmog'ini yaratmoqda. Bozor qiymatining kitob qiymatidan sezilarli darajada oshganligi tarixiy ko'rsatkichlari ushbu ekotizimni tasvirlaydi, bunda 0.19 ko'rsatkichi metrikaning holatini ifodalaydi. Aggressiv o'smalarga qarshi yo'naltirilgan dori vositalarining kutilayotgan sinov natijalari allaqachon narxga kiritilgan. Shu bilan birga, emitentning moliyaviy barqarorligi butunlay tashqi investitsiyalar va klinik ishlanmalarning muvaffaqiyatiga bog'liq.

Salarius Pharmaceuticals (SLRX) - Bozor kapitallashuvining balans qiymatiga nisbati 04.07.2022dan 08.01.2026gacha

SLRX (Salarius Pharmaceuticals Inc): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Salarius Pharmaceuticals|SLRX - Investitsiya uylarining umumiy prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Salarius|SLRX - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Salarius Pharmaceuticals|SLRX - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati salariuspharma.com|SLRX - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Salarius Pharmaceuticals|SLRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Salarius|SLRX - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Salarius|SLRX - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Salarius Pharmaceuticals
Fundamental baholash:SLRX (Salarius Pharmaceuticals)
Salarius Pharmaceuticals Inc tayyor mahsulotlari

Salarius Pharmaceuticals qat'iy patent qonunchiligi bilan himoyalangan noyob biologik preparatlarni ishlab chiqadi. Ushbu koeffitsient biznesning bozor qiymatini uning sof aktivlari bilan solishtirib, aksiyadorlar kutganlari va haqiqiy kapital o'rtasidagi farqni ochib beradi. Yuqori qiymatlar ilmiy salohiyat uchun qo'shimcha premiumni aks ettirsa, past qiymatlar fundamental past baholanganlikni ko'rsatadi. Investorlar uchun spekulyativ pufakni adolatli qiymatdan ajratish juda muhimdir. Kitob qiymatiga nisbatan bozor baholashining tarixi ushbu qayta baholash sikllarini aniq namoyish etadi.

Asosiy raqobatchilar

Kapitallashuvning sof aktivlarga nisbati BeiGene Ltd|halozyme.com (HALO) - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti XBIT|CVM (CEL-SCI Corporation) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi ostherapies.com (OSTX)|Bozor kapitallashuvining balans qiymatiga nisbati RADX (Radiopharm Theranostics)|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|ANL - Bozor qiymatining balans qiymatiga nisbati|VERU - Bozor qiymatining balans qiymatiga nisbati|TPST: Bozor kapitallashuvining balans qiymatiga nisbati|XLO (Xilio Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|RENB - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Mural Bio|KAPA (Kairos Pharma Ltd) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi onkuretherapeutics.com OKUR|Kapitallashuvning sof aktivlarga nisbati GDTC (CytoMed Therapeutics Limited)|Curis Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati APLM (Apollomics Corp)|Tharimmune Inc (THAR) - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati advanbiomed.com ADVB|GNPX (Genprex Inc) - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Calidi Biotherapeutics Inc. CLDI|Sof aktivlarga nisbatan bozor kapitallashuvi sunshinebiopharma.com|Xenetic Biosciences (XBIO) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Purple Biotech Ltd (PPBT)|Bozor kapitallashuvining balans qiymatiga nisbati AONC (American Oncology Network, Inc.)|BeiGene Ltd - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Checkpoint Therapeutics (CKPT)|ELEV: Balans qiymatiga nisbatan bozor qiymati|ICAD (icadmed.com) - Bozor qiymatining balans qiymatiga nisbati|Ikena Oncology (IKNA) - Kapitallashuvning sof aktivlarga nisbati|NTBL (Notable Labs Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati Viracta|Bozor kapitallashuvining balans qiymatiga nisbati MOR (MorphoSys AG)|Kapitallashuvning sof aktivlarga nisbati nayabiosciences.com (NAYA)|AAPGV: Bozor kapitallashuvining balans qiymatiga nisbati